Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Common Equity (2016 - 2025)

Historic Common Equity for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $43.7 million.

  • Seres Therapeutics' Common Equity rose 8268.74% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year increase of 8268.74%. This contributed to the annual value of $13.8 million for FY2024, which is 13072.94% up from last year.
  • As of Q3 2025, Seres Therapeutics' Common Equity stood at $43.7 million, which was up 8268.74% from $32.9 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Common Equity ranged from a high of $175.7 million in Q3 2021 and a low of -$87.1 million during Q2 2024
  • For the 5-year period, Seres Therapeutics' Common Equity averaged around $35.1 million, with its median value being $23.9 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 33310.19% in 2021, then tumbled by 51598.81% in 2023.
  • Seres Therapeutics' Common Equity (Quarter) stood at $131.5 million in 2021, then crashed by 91.8% to $10.8 million in 2022, then tumbled by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024, then soared by 217.01% to $43.7 million in 2025.
  • Its Common Equity was $43.7 million in Q3 2025, compared to $32.9 million in Q2 2025 and $50.5 million in Q1 2025.